(Q49399733)

20 February 2018

title

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. (English)

1 reference

20 February 2018

author name string

Shalin Shah

1

1 reference

20 February 2018

Kevin Wood

2

1 reference

20 February 2018

Brian Labadie

3

1 reference

20 February 2018

Brian Won

4

1 reference

20 February 2018

Ryan Brisson

5

1 reference

20 February 2018

Theodore Karrison

6

1 reference

20 February 2018

Thomas Hensing

7

1 reference

20 February 2018

Mark Kozloff

8

1 reference

20 February 2018

Riyue Bao

9

1 reference

20 February 2018

Jyoti D Patel

10

1 reference

20 February 2018

Jason J Luke

11

1 reference

20 February 2018

language of work or name

English

0 references

publication date

15 December 2017

1 reference

20 February 2018

published in

Oncotarget

1 reference

20 February 2018

volume

9

1 reference

20 February 2018

issue

4

1 reference

20 February 2018

page(s)

4375-4384

1 reference

20 February 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

1 reference

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Molecular and genetic properties of tumors associated with local immune cytolytic activity

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

An immune-active tumor microenvironment favors clinical response to ipilimumab

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5796980

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome

2 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29435109

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.23315

1 reference

20 February 2018

PMC publication ID

5796980

1 reference

20 February 2018

PubMed publication ID

29435109

1 reference

20 February 2018